Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and
targeted cancer therapies. Both general measures and specific pharmacologic …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Chemotherapy and targeted therapies have significantly improved the prognosis of
oncology patients. However, these antineoplastic treatments may also induce adverse …

Anthracyclines have contributed significantly to remarkable improvements in overall survival
and are regarded as the most effective cytostatic drug for cancer treatment in various …

Advances in cancer treatments have improved clinical outcomes, leading to an increasing
population of cancer survivors. However, this success is associated with high rates of short …

Anthracycline-induced cardiotoxicity (AIC) is a serious and common side effect of
anthracycline therapy. Identification of genes and genetic variants associated with AIC risk …

Anthracycline is a mainstay in treatment of many cancers including lymphoma and breast
cancer among many others. However, anthracycline treatment can be cardiotoxic. Although …

Background and aims Anthracyclines can cause cancer therapy-related cardiac dysfunction
(CTRCD). We aimed to assess whether statins prevent decline in left ventricular ejection …

Drug-induced cardiotoxicity is a life-threatening side effect of doxorubicin (DOX) treatment
that impacts patient prognosis and survival. In the majority of cases, the acute clinical form …